Search This Blog

Monday, June 1, 2026

Jade Biosciences reports positive Phase 1 JADE101 IgA nephropathy data

 

Jade Biosciences reports positive Phase 1 JADE101 IgA nephropathy data with ~70% sustained IgA reduction, plans Phase 3 trial in 1H 2027

  • Interim Phase 1 data show the ~70% IgA reduction was sustained after a single JADE101 dose.
  • Results support an every-12-week maintenance dosing regimen for JADE101 in IgA nephropathy.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)